Arvinas (ARVN)
Arvinas on one page: short interest, daily short volume, fails to deliver, planned sales, large holders, 13F holders, earnings dates and insider trades. Listed on Nasdaq, classified by the SEC as pharmaceutical preparations.
5.6M
Short interest
settlement 2026-10-15
8.2
Days to cover
+1.6 days vs prior
32.0%
Short share of volume
2026-11-02
400
Fails to deliver
settlement 2026-09-18
Wed 4 Nov
Next earnings
estimated date
$0
Insider flow, 90 days
0 buys, 0 sells
As of 2026-11-02.
Short interest
FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSONAs of 15 October 2026, short interest in ARVN is 5,592,327 shares, up 606,146 shares over the last month. Over the last 48 readings it ranged from 3,979,917 shares (15 July 2026) to 12,701,352 shares (28 February 2025). At the reported average volume of 684K shares a day that is 8.2 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/arvn" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-10-15 | 5,592,327 | +3.8% | 684,378 | 8.17 |
| 2026-09-30 | 5,389,277 | +8.1% | 819,217 | 6.58 |
| 2026-09-15 | 4,986,181 | +5.8% | 891,583 | 5.59 |
| 2026-08-31 | 4,711,553 | +16.3% | 585,801 | 8.04 |
| 2026-08-14 | 4,051,773 | +1.4% | 1,216,269 | 3.33 |
| 2026-07-31 | 3,995,358 | +0.4% | 574,230 | 6.96 |
| 2026-07-15 | 3,979,917 | -6.8% | 601,288 | 6.62 |
| 2026-06-30 | 4,268,156 | -5.0% | 930,354 | 4.59 |
| 2026-06-15 | 4,493,472 | -4.5% | 775,037 | 5.80 |
| 2026-05-29 | 4,706,811 | -6.6% | 800,178 | 5.88 |
| 2026-05-15 | 5,037,367 | +14.0% | 1,149,991 | 4.38 |
| 2026-04-30 | 4,417,179 | +0.7% | 607,875 | 7.27 |
| 2026-04-15 | 4,388,293 | -2.6% | 899,156 | 4.88 |
| 2026-03-31 | 4,506,829 | -5.8% | 974,243 | 4.63 |
| 2026-03-13 | 4,786,465 | +11.5% | 711,085 | 6.73 |
| 2026-02-27 | 4,292,094 | +6.1% | 853,112 | 5.03 |
| 2026-02-13 | 4,046,761 | -5.1% | 729,571 | 5.55 |
| 2026-01-30 | 4,262,275 | -15.6% | 720,790 | 5.91 |
| 2026-01-15 | 5,052,067 | +4.0% | 785,944 | 6.43 |
| 2025-12-31 | 4,859,281 | -27.9% | 783,267 | 6.20 |
| 2025-12-15 | 6,742,263 | +4.0% | 1,134,669 | 5.94 |
| 2025-11-28 | 6,483,114 | -20.4% | 3,411,670 | 1.90 |
| 2025-11-14 | 8,142,090 | +4.9% | 2,061,860 | 3.95 |
| 2025-10-31 | 7,764,976 | +4.1% | 2,478,747 | 3.13 |
| 2025-10-15 | 7,459,736 | -6.6% | 2,403,653 | 3.10 |
| 2025-09-30 | 7,986,348 | -16.7% | 2,653,676 | 3.01 |
| 2025-09-15 | 9,587,995 | +11.9% | 1,353,259 | 7.09 |
| 2025-08-29 | 8,567,039 | +3.0% | 1,369,654 | 6.25 |
| 2025-08-15 | 8,321,083 | +9.8% | 2,292,076 | 3.63 |
| 2025-07-31 | 7,578,094 | -3.1% | 1,935,915 | 3.91 |
| 2025-07-15 | 7,818,081 | +9.4% | 1,758,968 | 4.44 |
| 2025-06-30 | 7,147,663 | -14.2% | 1,901,769 | 3.76 |
| 2025-06-13 | 8,325,671 | +7.7% | 2,303,731 | 3.61 |
| 2025-05-30 | 7,730,211 | -6.1% | 1,933,548 | 4.00 |
| 2025-05-15 | 8,231,632 | +11.3% | 4,357,283 | 1.89 |
| 2025-04-30 | 7,399,181 | -4.2% | 2,010,073 | 3.68 |
| 2025-04-15 | 7,726,869 | +20.9% | 2,665,499 | 2.90 |
| 2025-03-31 | 6,390,998 | -28.2% | 2,552,120 | 2.50 |
| 2025-03-14 | 8,900,480 | -29.9% | 4,234,386 | 2.10 |
| 2025-02-28 | 12,701,352 | +10.1% | 1,385,222 | 9.17 |
| 2025-02-14 | 11,540,484 | +10.6% | 1,146,259 | 10.07 |
| 2025-01-31 | 10,436,151 | +6.9% | 815,797 | 12.79 |
| 2025-01-15 | 9,763,059 | +3.0% | 739,391 | 13.20 |
| 2024-12-31 | 9,479,102 | -1.4% | 1,099,988 | 8.62 |
| 2024-12-13 | 9,614,234 | +6.6% | 914,769 | 10.51 |
| 2024-11-29 | 9,020,282 | +5.6% | 694,260 | 12.99 |
| 2024-11-15 | 8,538,924 | -3.0% | 626,826 | 13.62 |
| 2024-10-31 | 8,804,546 | -5.5% | 631,683 | 13.94 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 2 November 2026, the short share of ARVN volume is 32.0%, down 26.3 points over the last five sessions. Over the last 30 readings it ranged from 30.0% (28 October 2026) to 67.0% (29 September 2026). The latest reading sits at the bottom of that range. The latest reading is 21.3 points below the 30-session average of 53.3%, on 441K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-11-02 | 141K | 441K | 32.0% | 26 |
| 2026-10-30 | 159K | 311K | 51.3% | 0 |
| 2026-10-29 | 112K | 235K | 47.5% | 2,000 |
| 2026-10-28 | 132K | 441K | 30.0% | 0 |
| 2026-10-27 | 172K | 374K | 45.9% | 0 |
| 2026-10-26 | 132K | 226K | 58.3% | 1,031 |
| 2026-10-23 | 99K | 177K | 55.8% | 128 |
| 2026-10-22 | 118K | 195K | 60.3% | 0 |
| 2026-10-21 | 89K | 182K | 49.0% | 0 |
| 2026-10-20 | 74K | 146K | 50.7% | 0 |
| 2026-10-19 | 182K | 316K | 57.6% | 1,728 |
| 2026-10-16 | 103K | 214K | 48.4% | 0 |
| 2026-10-15 | 89K | 191K | 46.4% | 0 |
| 2026-10-14 | 142K | 278K | 50.9% | 0 |
| 2026-10-13 | 149K | 238K | 62.4% | 1,300 |
| 2026-10-12 | 121K | 190K | 63.7% | 0 |
| 2026-10-09 | 122K | 189K | 64.7% | 0 |
| 2026-10-08 | 129K | 292K | 44.2% | 0 |
| 2026-10-07 | 119K | 197K | 60.1% | 0 |
| 2026-10-06 | 86K | 152K | 56.6% | 0 |
| 2026-10-05 | 98K | 167K | 58.6% | 252 |
| 2026-10-02 | 103K | 189K | 54.6% | 0 |
| 2026-10-01 | 119K | 206K | 57.8% | 1,408 |
| 2026-09-30 | 134K | 286K | 47.0% | 775 |
| 2026-09-29 | 96K | 144K | 67.0% | 0 |
| 2026-09-28 | 82K | 148K | 55.3% | 900 |
| 2026-09-25 | 129K | 246K | 52.7% | 0 |
| 2026-09-24 | 228K | 365K | 62.5% | 12 |
| 2026-09-23 | 189K | 312K | 60.5% | 3,298 |
| 2026-09-22 | 94K | 202K | 46.7% | 1,852 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 18 September 2026, the fails-to-deliver balance in ARVN is 400 shares, down 288 shares over the last settlement date. Over the last 30 readings it ranged from 1 share (13 July 2026) to 658,066 shares (22 December 2025). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-09-18 | 400 | $8.31 | $3K |
| 2026-09-08 | 688 | $9.39 | $6K |
| 2026-08-24 | 500 | $9.37 | $5K |
| 2026-08-11 | 2 | $8.99 | $18 |
| 2026-08-06 | 3,907 | $8.40 | $33K |
| 2026-07-23 | 100 | $8.26 | $826 |
| 2026-07-22 | 100 | $8.26 | $826 |
| 2026-07-15 | 74 | $8.27 | $612 |
| 2026-07-13 | 1 | $8.27 | $8 |
| 2026-07-09 | 1,411 | $8.56 | $12K |
| 2026-07-01 | 73 | $8.31 | $607 |
| 2026-06-29 | 1,073 | $8.00 | $9K |
| 2026-06-22 | 3,898 | $7.67 | $30K |
| 2026-06-17 | 65 | $7.42 | $482 |
| 2026-06-15 | 378 | $7.58 | $3K |
| 2026-06-09 | 28 | $7.15 | $200 |
| 2026-05-19 | 299 | $8.78 | $3K |
| 2026-05-15 | 10,007 | $9.42 | $94K |
| 2026-04-23 | 10 | $10.63 | $106 |
| 2026-03-17 | 84 | $12.28 | $1K |
| 2026-03-13 | 306 | $12.48 | $4K |
| 2026-03-06 | 27 | $13.72 | $370 |
| 2026-03-05 | 290 | $13.76 | $4K |
| 2026-02-02 | 15 | $13.38 | $201 |
| 2026-01-27 | 125 | $13.29 | $2K |
| 2025-12-31 | 56 | $11.73 | $657 |
| 2025-12-30 | 1,794 | $11.90 | $21K |
| 2025-12-22 | 658,066 | $11.68 | $7.7M |
| 2025-12-08 | 7,527 | $12.79 | $96K |
| 2025-12-05 | 64 | $12.55 | $803 |
Insider trades
SEC Form 4, newest first. JSONNo open-market insider trades were reported for ARVN in the last 90 days. The most recent filings are listed below. Latest filing: Smaldone Alsup Laurie (Director) on 2026-06-24.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-06-24 | Smaldone Alsup Laurie | Director | Grant | 16K | $0.00 | $0 | 42K |
| 2026-06-24 | Norwalk Leslie V | Director | Grant | 16K | $0.00 | $0 | 42K |
| 2026-06-24 | Morrison Briggs | Director | Grant | 16K | $0.00 | $0 | 112K |
| 2026-06-24 | Kennedy Edward Moore Jr. | Director | Grant | 16K | $0.00 | $0 | 55K |
| 2026-06-24 | Cunningham Everett | Director | Grant | 16K | $0.00 | $0 | 42K |
| 2026-06-24 | Bain Linda | Director | Grant | 16K | $0.00 | $0 | 42K |
| 2026-06-24 | Saik Andrew | Chief Financial Officer | Sell | 6K | $8.16 | $46K | 187K |
| 2026-06-17 | Cacace Angela M | Chief Scientific Officer | Sell | 3K | $7.59 | $20K | 180K |
| 2026-05-21 | Teel Randy | President and CEO | Sell | 2K | $9.04 | $20K | 285K |
| 2026-05-11 | Saik Andrew | Chief Financial Officer | Sell | 11K | $9.94 | $111K | 193K |
| 2026-05-11 | Loomis David K | VP, Chief Accounting Officer | Sell | 2K | $9.94 | $19K | 40K |
| 2026-05-11 | Cacace Angela M | Chief Scientific Officer | Sell | 10K | $9.94 | $96K | 183K |
| 2026-05-11 | Berkowitz Noah | Chief Medical Officer | Sell | 11K | $9.94 | $110K | 191K |
| 2026-05-11 | Teel Randy | President and CEO | Sell | 10K | $9.94 | $96K | 287K |
| 2026-03-18 | Berkowitz Noah | Chief Medical Officer | Sell | 6K | $11.10 | $71K | 203K |
| 2026-03-06 | Morrison Briggs | Director | Buy | 20K | $13.40 | $268K | 96K |
| 2026-02-27 | Houston John G | Director | Sell | 12K | $13.14 | $155K | 1.1M |
| 2026-02-27 | Houston John G | Director | Sell | 19K | $13.24 | $249K | 1.1M |
| 2026-02-27 | Houston John G | Director | Sell | 5K | $13.24 | $62K | 1.2M |
| 2026-02-26 | Teel Randy | President and CEO | Grant | 147K | $0.00 | $0 | 297K |
| 2026-02-26 | Loomis David K | VP, Chief Accounting Officer | Grant | 12K | $0.00 | $0 | 42K |
| 2026-02-26 | Cacace Angela M | Chief Scientific Officer | Grant | 45K | $0.00 | $0 | 193K |
| 2026-02-26 | Berkowitz Noah | Chief Medical Officer | Grant | 45K | $0.00 | $0 | 209K |
| 2026-02-26 | Saik Andrew | Chief Financial Officer | Grant | 45K | $0.00 | $0 | 204K |
| 2026-02-26 | Teel Randy | President and CEO | Grant | 148K | $0.00 | $0 | 297K |
| 2026-02-23 | Loomis David K | Chief Accounting Officer | Sell | 1K | $12.16 | $13K | 30K |
| 2026-02-23 | Cacace Angela M | Chief Scientific Officer | Sell | 3K | $12.16 | $31K | 148K |
| 2026-02-23 | Cacace Angela M | Chief Scientific Officer | Sell | 1K | $12.16 | $13K | 150K |
| 2026-02-23 | Teel Randy | President and CEO | Sell | 4K | $12.16 | $46K | 150K |
| 2026-02-23 | Teel Randy | President and CEO | Sell | 1K | $12.16 | $13K | 153K |
| 2026-02-13 | Teel Randy | President and CEO | Sell | 4K | $11.89 | $52K | 154K |
| 2026-02-13 | Saik Andrew | Chief Financial Officer | Sell | 5K | $11.89 | $61K | 159K |
| 2026-02-13 | Cacace Angela M | Chief Scientific Officer | Sell | 5K | $11.89 | $55K | 151K |
| 2026-02-13 | Berkowitz Noah | Chief Medical Officer | Sell | 6K | $11.89 | $68K | 164K |
| 2026-02-13 | Loomis David K | Chief Accounting Officer | Sell | 1K | $11.89 | $12K | 31K |
| 2025-11-07 | Loomis David K | Chief Accounting Officer | Sell | 230 | $9.89 | $2K | 32K |
| 2025-09-22 | Morrison Briggs | Director | Buy | 30K | $7.57 | $227K | 76K |
| 2025-06-25 | Smaldone Alsup Laurie | Director | Grant | 16K | $0.00 | $0 | 26K |
| 2025-06-25 | Morrison Briggs | Director | Grant | 16K | $0.00 | $0 | 46K |
| 2025-06-25 | YOUNG JOHN D | Director | Grant | 16K | $0.00 | $0 | 26K |
| 2025-06-25 | Bain Linda | Director | Grant | 16K | $0.00 | $0 | 26K |
| 2025-06-25 | Kennedy Edward Moore Jr. | Director | Grant | 16K | $0.00 | $0 | 39K |
| 2025-06-25 | Cunningham Everett | Director | Grant | 16K | $0.00 | $0 | 26K |
| 2025-06-25 | Norwalk Leslie V | Director | Grant | 16K | $0.00 | $0 | 26K |
| 2025-06-25 | AGARWAL SUNIL | Director | Grant | 16K | $0.00 | $0 | 30K |
| 2025-06-24 | Saik Andrew | Chief Financial Officer | Sell | 6K | $7.61 | $43K | 164K |
| 2025-06-17 | Cacace Angela M | Chief Scientific Officer | Sell | 3K | $7.49 | $19K | 154K |
| 2025-05-09 | Berkowitz Noah | Chief Medical Officer | Grant | 60K | $0.00 | $0 | 170K |
| 2025-05-09 | Cacace Angela M | Chief Scientific Officer | Grant | 60K | $0.00 | $0 | 157K |
| 2025-05-09 | Saik Andrew | Chief Financial Officer | Grant | 60K | $0.00 | $0 | 170K |
| 2025-05-09 | Loomis David K | Chief Accounting Officer | Grant | 12K | $0.00 | $0 | 31K |
| 2025-03-18 | Berkowitz Noah | Chief Medical Officer | Sell | 9K | $8.59 | $74K | 110K |
| 2025-02-24 | Houston John G | President and CEO | Sell | 5K | $16.55 | $85K | 1.2M |
| 2025-02-24 | Houston John G | President and CEO | Sell | 26K | $16.75 | $439K | 1.2M |
| 2025-02-24 | Taylor Ian | President, R&D | Sell | 7K | $16.75 | $123K | 161K |
| 2025-02-24 | Taylor Ian | President, R&D | Sell | 2K | $16.55 | $28K | 159K |
| 2025-02-24 | Cacace Angela M | Chief Scientific Officer | Sell | 3K | $16.75 | $51K | 98K |
| 2025-02-24 | Cacace Angela M | Chief Scientific Officer | Sell | 1K | $16.55 | $19K | 97K |
| 2025-02-24 | Loomis David K | Chief Accounting Officer | Sell | 1K | $16.75 | $20K | 19K |
| 2025-02-13 | Houston John G | President and CEO | Grant | 152K | $0.00 | $0 | 1.2M |
| 2025-02-13 | Cacace Angela M | Chief Scientific Officer | Grant | 49K | $0.00 | $0 | 101K |
| 2025-02-13 | Berkowitz Noah | Chief Medical Officer | Grant | 55K | $0.00 | $0 | 119K |
| 2025-02-13 | Taylor Ian | Chief Scientific Officer | Grant | 21K | $0.00 | $0 | 168K |
| 2025-02-13 | Saik Andrew | Chief Financial Officer | Grant | 49K | $0.00 | $0 | 111K |
| 2025-02-13 | Loomis David K | Chief Accounting Officer | Grant | 11K | $0.00 | $0 | 19K |
| 2024-11-07 | Loomis David K | Chief Accounting Officer | Sell | 231 | $27.69 | $6K | 8K |
| 2024-06-24 | Saik Andrew | Chief Financial Officer | Grant | 61K | $0.00 | $0 | 61K |
| 2024-06-17 | Cacace Angela M | Chief Scientific Officer | Grant | 16K | $0.00 | $0 | 52K |
| 2024-05-29 | Smaldone Alsup Laurie | Director | Grant | 6K | $0.00 | $0 | 10K |
| 2024-05-29 | Norwalk Leslie V | Director | Grant | 6K | $0.00 | $0 | 10K |
| 2024-05-29 | YOUNG JOHN D | Director | Grant | 6K | $0.00 | $0 | 10K |
| 2024-05-29 | Morrison Briggs | Director | Grant | 6K | $0.00 | $0 | 30K |
| 2024-05-29 | AGARWAL SUNIL | Director | Grant | 6K | $0.00 | $0 | 14K |
| 2024-05-29 | Kennedy Edward Moore Jr. | Director | Grant | 6K | $0.00 | $0 | 23K |
| 2024-05-29 | Cunningham Everett | Director | Grant | 6K | $0.00 | $0 | 10K |
| 2024-05-29 | Bain Linda | Director | Grant | 6K | $0.00 | $0 | 10K |
| 2024-05-21 | Teel Randy | Int. Chief Financial Officer | Grant | 13K | $0.00 | $0 | 59K |
| 2024-03-18 | Berkowitz Noah | Chief Medical Officer | Grant | 63K | $0.00 | $0 | 63K |
| 2024-02-23 | Loomis David K | Chief Accounting Officer | Grant | 6K | $0.00 | $0 | 9K |
| 2024-02-23 | Taylor Ian | Chief Scientific Officer | Sell | 2K | $47.05 | $80K | 148K |
| 2024-02-23 | Taylor Ian | Chief Scientific Officer | Grant | 39K | $0.00 | $0 | 149K |
| 2024-02-23 | Peck Ronald | Chief Medical Officer | Sell | 2K | $47.05 | $80K | 68K |
| 2024-02-23 | Peck Ronald | Chief Medical Officer | Grant | 39K | $0.00 | $0 | 69K |
| 2024-02-23 | Cassidy Sean A | Chief Financial Officer | Sell | 2K | $47.05 | $80K | 182K |
| 2024-02-23 | Houston John G | President and CEO | Sell | 5K | $47.05 | $244K | 1.0M |
| 2024-02-23 | Houston John G | President and CEO | Grant | 124K | $0.00 | $0 | 1.0M |
| 2024-01-04 | Taylor Ian | Chief Scientific Officer | Exercise or conversion | 8K | $16.00 | $132K | 110K |
| 2023-11-08 | Loomis David K | Chief Accounting Officer | Sell | 229 | $17.05 | $4K | 8K |
| 2023-08-11 | Peck Ronald | Chief Medical Officer | Sell | 1K | $24.39 | $32K | 30K |
| 2023-08-11 | Peck Ronald | Chief Medical Officer | Exercise or conversion | 4K | price not stated in the filing | not stated | 31K |
| 2023-06-15 | AGARWAL SUNIL | Director | Grant | 8K | $0.00 | $0 | 8K |
| 2023-06-15 | Bain Linda | Director | Grant | 4K | $0.00 | $0 | 4K |
| 2023-06-15 | Cunningham Everett | Director | Grant | 4K | $0.00 | $0 | 4K |
| 2023-06-15 | DIXON WENDY L | Director | Grant | 4K | $0.00 | $0 | 9K |
| 2023-06-15 | Kennedy Edward Moore Jr. | Director | Grant | 4K | $0.00 | $0 | 18K |
| 2023-06-15 | Morrison Briggs | Director | Grant | 4K | $0.00 | $0 | 24K |
| 2023-06-15 | Norwalk Leslie V | Director | Grant | 4K | $0.00 | $0 | 4K |
| 2023-06-15 | Smaldone Alsup Laurie | Director | Grant | 4K | $0.00 | $0 | 4K |
| 2023-06-15 | YOUNG JOHN D | Director | Grant | 4K | $0.00 | $0 | 4K |
| 2023-03-01 | Cassidy Sean A | Chief Financial Officer | Exercise or conversion | 5K | price not stated in the filing | not stated | 185K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Planned sales (Form 144)
Newest first. JSON13 Form 144 notices on file for ARVN worth $1.9M at the prices reported; 3 in the last 90 days worth $604K. Latest: SUNIL AGARWAL filed on 2026-09-22 to sell 23,105 shares ($196K) from 2026-09-22.
| Filed | Seller | Shares | Market value | Of outstanding | Sale from | Broker |
|---|---|---|---|---|---|---|
| 2026-09-22 | SUNIL AGARWALDirector | 23K | $196K | 0.035% | 2026-09-22 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-09-09 | NOAH C BERKOWITZFormer Officer | 37K | $329K | 0.057% | 2026-09-09 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-09-04 | NOAH C BERKOWITZFormer Officer | 8K | $78K | 0.013% | 2026-09-04 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-08-04 | NOAH C BERKOWITZOfficer | 30K | $264K | 0.046% | 2026-08-04 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-07-09 | NOAH C BERKOWITZFormer Affiliate | 24K | $202K | 0.037% | 2026-07-09 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-03-17 | Noah BerkowitzOfficer | 6K | $72K | 0.009% | 2026-03-18 | Morgan Stanley Smith Barney LLC |
| 2026-02-27 | John G. Houstonformer President and CEO, Director | 35K | $466K | 0.055% | 2026-02-27 | Morgan Stanley Smith Barney LLC |
| 2026-02-23 | Angela CacaceOfficer | 4K | $44K | 0.006% | 2026-02-23 | Morgan Stanley Smith Barney LLC |
| 2026-02-23 | Randy TeelOfficer, Director | 5K | $58K | 0.007% | 2026-02-23 | Morgan Stanley Smith Barney LLC |
| 2026-02-13 | Noah BerkowitzOfficer | 6K | $68K | 0.009% | 2026-02-13 | Morgan Stanley Smith Barney LLC |
| 2026-02-13 | Angela CacaceOfficer | 5K | $55K | 0.007% | 2026-02-13 | Morgan Stanley Smith Barney LLC |
| 2026-02-13 | Randy TeelOfficer | 4K | $52K | 0.007% | 2026-02-13 | Morgan Stanley Smith Barney LLC |
| 2026-02-13 | Andrew SaikOfficer | 5K | $61K | 0.008% | 2026-02-13 | Morgan Stanley Smith Barney LLC |
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON3 holders report 5% or more of ARVN in their latest filing, all on Schedule 13G (passive). The largest reported stake is Vanguard Portfolio Management at 6.1% of the class (3,917,671 shares), filed 2026-04-28 for an event on 2026-03-31.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-08-14 | 13G/Ano. 1 | D. E. Shaw & Co., L.P.investment adviser, partnership | 3.5M | 5.4% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 1 | David E. Shawindividual | 3.5M | 5.4% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 1 | D. E. Shaw & Co., L.L.C.other entity | 3.1M | 4.7% | 2026-06-30 |
| 2026-04-28 | 13G | Vanguard Portfolio Managementinvestment adviser | 3.9M | 6.1% | 2026-03-31 |
| 2026-03-26 | 13G/Ano. 5 | The Vanguard Groupinvestment adviser | 0 | 0.0% | 2026-03-13 |
| 2025-11-14 | 13G/Ano. 2 | Kenneth Griffinparent holding company, individual | 264K | 0.4% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 2 | Citadel Securities LLCbroker-dealer, other entity | 121K | 0.2% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 2 | Citadel Advisors LLCinvestment adviser, parent holding company, other entity | 143K | 0.2% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 2 | Citadel Advisors Holdings LPparent holding company, partnership | 143K | 0.2% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 2 | Citadel GP LLCparent holding company, other entity | 143K | 0.2% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 2 | Citadel Securities Group LPparent holding company, partnership | 121K | 0.2% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 2 | Citadel Securities GP LLCparent holding company, other entity | 121K | 0.2% | 2025-09-30 |
| 2025-10-15 | 13D/Ano. 2 | Arsani Williamindividual, parent holding company | 2.5M | 3.4% | 2025-10-13 |
| 2025-10-15 | 13D/Ano. 2 | Logos Global Management LPinvestment adviser, partnership | 2.5M | 3.4% | 2025-10-13 |
| 2025-10-15 | 13D/Ano. 2 | Logos Global Management GP LLCparent holding company, other entity | 2.5M | 3.4% | 2025-10-13 |
| 2025-10-15 | 13D/Ano. 2 | Logos Global Master Fund LPpartnership | 2.0M | 2.7% | 2025-10-13 |
| 2025-10-15 | 13D/Ano. 2 | Logos GP LLCparent holding company, other entity | 2.0M | 2.7% | 2025-10-13 |
| 2025-10-15 | 13D/Ano. 2 | Graham Walmsleyindividual, parent holding company | 500K | 0.7% | 2025-10-13 |
| 2025-10-15 | 13D/Ano. 2 | Logos Opportunities Fund IV GP LLCparent holding company, other entity | 500K | 0.7% | 2025-10-13 |
| 2025-10-15 | 13D/Ano. 2 | Logos Opportunities Fund IV LPpartnership | 500K | 0.7% | 2025-10-13 |
13F holders
Tracked managers holding ARVN at their latest 13F. JSON7 of the 30 tracked managers held ARVN at their latest 13F, $68.3M in total at quarter-end prices. D. E. Shaw & Co. is the largest at $29.0M (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 3 added shares and 4 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| D. E. Shaw & Co. | 2026-06-30 | 3.5M | $29.0M | 0.01% | -143K |
| Two Sigma Investments | 2026-06-30 | 2.6M | $21.4M | 0.02% | +741K |
| Citadel Advisors | 2026-06-30 | 621K | $5.2M | 0.00% | -560K |
| AQR Capital Management | 2026-06-30 | 602K | $5.0M | 0.00% | +317K |
| Millennium Management | 2026-06-30 | 574K | $4.8M | 0.00% | -2K |
| Renaissance Technologies | 2026-06-30 | 215K | $1.8M | 0.00% | new |
| Point72 Asset Management | 2026-06-30 | 141K | $1.2M | 0.00% | -89K |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
What this page is
Arvinas in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows Arvinas (ARVN), SEC CIK 1655759, listed on Nasdaq, classified by the SEC as pharmaceutical preparations. The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-10-15.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-11-02.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-09-18.JSON and CSV
- Planned sales
- SEC EDGAR Form 144Source: SEC.New notices appear shortly after the SEC posts them; a notice is filed on or before the sale. Latest 2026-09-22.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-08-14.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-08-04.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-06-24.JSON and CSV
- Company record
- EDGAR filing index for CIK 1655759Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as pharmaceutical preparations
Other company pages
- STESTERIS
- STLDSteel Dynamics
- STRCStrategy
- STRLSterling Infrastructure
- STTState Street
- STXSeagate Technology Holdings
- STZConstellation Brands
- SUISun Communities
- SUNBSunbelt Rentals Holdings
- SWSmurfit Westrock
- SWKStanley Black & Decker
- SWKSSkyworks Solutions
- SXTCChina SXT Pharmaceuticals
- SYFSynchrony Financial
- SYKStryker
- SYNASynaptics
Datasets
Frequently Asked Questions
How much of ARVN is sold short?
5,592,327 shares were held short at the 2026-10-15 settlement, 8.2 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.
What is ARVN's daily short volume?
On 2026-11-02, 141,028 of the 440,825 ARVN shares reported to FINRA were sold short, 32.0% of the day's reported volume. Short volume is a flow for one day, not a position.
Does ARVN have fails to deliver?
The SEC's latest file shows 400 ARVN shares failed to deliver at settlement 2026-09-18. Fails are reported per settlement date and published twice a month with a lag.
Are ARVN insiders buying or selling?
No open-market insider trades were reported for ARVN in the last 90 days. The most recent filings are listed below. Latest filing: Smaldone Alsup Laurie (Director) on 2026-06-24.
Have ARVN insiders filed to sell?
13 Form 144 notices on file for ARVN worth $1.9M at the prices reported; 3 in the last 90 days worth $604K. Latest: SUNIL AGARWAL filed on 2026-09-22 to sell 23,105 shares ($196K) from 2026-09-22.
Who owns 5% or more of ARVN?
3 holders report 5% or more of ARVN in their latest filing, all on Schedule 13G (passive). The largest reported stake is Vanguard Portfolio Management at 6.1% of the class (3,917,671 shares), filed 2026-04-28 for an event on 2026-03-31.
Which tracked 13F managers own ARVN?
7 of the 30 tracked 13F managers held ARVN shares at their latest filing, $68.3M in all. The largest: D. E. Shaw & Co. (3.5M shares, $29.0M), Two Sigma Investments (2.6M shares, $21.4M), Ken Griffin's Citadel Advisors (621K shares, $5.2M), Cliff Asness's AQR Capital Management (602K shares, $5.0M), Izzy Englander's Millennium Management (574K shares, $4.8M), Renaissance Technologies (215K shares, $1.8M). The table above lists all 7.
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.